SEC Form 4 · accession 0001127602-15-021137
BIOCRYST PHARMACEUTICALS INC · BCRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jon P Stonehouse
Officer — President & CEO · Director
Period of report
Jun 19, 2015
Accepted (ET)
Jun 22, 2015 · 4:34 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882796
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 19, 2015 | M | 20,000 | $1.20 | A | 670,869 | D | |
| Common StockF1,F2 | Jun 19, 2015 | S | 20,000 | $15.02 | D | 650,869 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Emp. Stock Option (Right to Buy)F1 | $1.20 | Jun 19, 2015 | M | 20,000 | D | Mar 2, 2010 | Mar 2, 2019 | Common Stock | 20,000 | 80,000 | D |
Explanation of responses
- F1This transaction was made pursuant to a Rule 105-b trading plan adopted by the reporting person on December 30, 2014.
- F2The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $15.00 to $15.10. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.